INTRODUCTION
Receptor-type protein tyrosine kinases consist of a large group of cell surface proteins with unique structures and biological activities [1, 2] . Abnormal accumulation and activation of receptor tyrosine kinases have been implicated in the initiation and progression of a variety of malignancies including tumors derived from breast and kidney [3, 4] . The MET proto-oncogene family is a subfamily of receptor tyrosine kinases that plays an important role in tumorigenesis and invasiveness of certain epithelial carcinomas [5] . Three members of the MET family, MET, C-Sea, and RON, have been identified [6 -8] . MET is the receptor for hepatocyte growth factor/scatter factor (HGF/SF) [9] and has well-described roles in cell transformation and tumor development [10, 11] . The C-Sea gene encodes a chicken cell surface receptor that is often overexpressed in transformed fibroblasts [8] . Recent studies have indicated that C-Sea might be the chicken homologue of human RON [12] . RON is the specific receptor for macrophage-stimulating protein (MSP) [13] [14] [15] , also known as HGF-like protein [16] . In cells expressing MET or RON, increased cell motility and matrix invasiveness have been demonstrated [17, 18] , suggesting that these two receptors may regulate motileinvasive phenotypes of certain epithelial tumors in vivo. Recently, genetic analysis of hereditary papillary renal carcinomas has shown that germline and somatic mutations occur in the kinase domain of the MET gene [4, 19] . These studies established the cancer-causing effect of MET in the initiation of hereditary papillary renal tumors [4, 17, 19] .
The cDNA encoding RON was originally cloned from a cDNA library of human foreskin keratinocytes [7] . RON is also known as STK in mouse [20] . Mature RON is a 180-kDa heterodimer composed of a 40-kDa extracellular ␣ chain and a 150-kDa transmembrane ␤ chain with intrinsic protein tyrosine kinase activity [13, 14] . Expression of RON has been found in certain types of tissue macrophages [21, 22] , erythroleukemia cell lines [23] , and many epithelial tumor cells [24, 25] . Currently, the roles of RON in cell transformation and tumor development are still unknown. Naturally oc-curring oncogenic forms of RON have not yet been identified. However, recent studies have found that RON is overexpressed in many primary breast carcinomas [26] . In the human stomach cancer cell line KATO III, a splicing variant of RON was identified [27] . This RON variant is characterized by an in-frame deletion of 49 amino acids in the extracellular domain of the RON ␤ chain, which results in constitutive tyrosine phosphorylation [27] . Other studies have also demonstrated that activation of RON causes invasive growth and motile activities of certain epithelial tumor cells [18, 25, 26] . Considering these facts, it was suggested that RON might be involved in the process of epithelial tumor metastasis [18, 25, 26] .
The present work was undertaken to study RON expression and its biological effects on human colon carcinoma cell lines. At present, information related to RON in colon carcinoma cells is not available. Therefore, we sought to determine whether RON is overexpressed or constitutively activated in colon carcinoma cell lines. Analysis of possible mutations in the kinase domain of the RON gene was also conducted in five colon carcinoma cell lines. Moreover, we studied the functions of RON in colon epithelial cells with regard to the induction of cell migration, invasion, and survival. Our data showed that RON is overexpressed and constitutively activated in colon carcinoma cell lines. Activation of RON confers in vitro the invasive phenotype in SV-40 transformed colon epithelial cells.
MATERIALS AND METHODS
Cell lines. Human colon epithelial cell lines FHC, CoTr, Colo201, DLD-1, HCT116, HT-29, SW620, and SW837 were from ATCC (Rockville, MD). FHC is a normal colon epithelial cell line. CoTr is a SV-40 large T antigen-transformed colon epithelial cell line. Colo201, DLD-1, HCT116, HT-29, SW620, and SW837 all are carcinoma cell lines. RE7 is a clone of Madin-Darby canine kidney (MDCK) cells transfected with a human RON cDNA [13] .
Reagents. MSP was kindly provided by Dr. E. J. Leonard (National Cancer Institute, Frederick, MD). Mouse mAb to human RON (clone ID2) and rabbit IgG antibody against the synthetic C-terminal peptide of the RON ␤ chain were as described [13] . Mouse mAb to phosphotyrosine (clone 4G10) was from Upstate Biotechnology Inc. (Lake Placid, NY). A plasmid designed to express the glutathione S-transferase (GST)-c-jun (amino acids 1-79) fusion protein [28] was kindly provided by Dr. X. Xu (Nanogen Inc., San Diego, CA). Enhanced chemiluminiscence (ECL) detection reagents were from Amersham (Arlington Heights, IL). Cell culture medium was from Life Technologies (Gaithersburg, MD). Other chemicals were from Fisher Scientific (Pittsburgh, PA).
RT-PCR and DNA sequencing. Total RNAs were isolated from HT-29 cells using TRIzol (Life Technologies). Reverse transcription was carried out using total RNAs (2 g) with a SuperScript Preamplification Kit (Life Technologies). PCR was performed as described [27] . The oligomers used to clone the RON⌬p160 cDNA were designed on the basis of the RON cDNA sequences [7] : pair 1, sense oligomer from nucleotides Ϫ183 to Ϫ164 (5Ј-GAGGGCC GGGAAGG-GATTTG-3Ј) and antisense oligomer from nucleotides 2292 to 2315 (5Ј-TGCCCAGGTACCTGGTTCCTGGA-3Ј); pair 2, sense oligomer from nucleotides 2165 to 2189 (5Ј-ACCAGCCGGGCTGTGCTGGT-CAAT-3Ј) and antisense oligomer from nucleotides 3650 to 3672 (5Ј-ACCTGGCTGCGCGGAACTGCAT-3Ј); and pair 3, sense oligomer from nucleotides 3122 to 3145 (5Ј-ACCACTTGTGTCCATG-GAGCATCC-3Ј) and antisense oligomer from nucleotides 4366 to 4389 (5Ј-CCATTAGGTCCCTCACTCCACAGA-3Ј). Three amplified fragments were designated fragments I, II, and III, respectively. Double-stranded DNA sequencing was performed at the University of Colorado Cancer Center DNA Sequence Core Facility.
Genomic DNA isolation and mutational analysis. Genomic DNAs were isolated from five colon carcinoma cell lines as described [4] . PCR-based single-stranded conformation polymorphism (SSCP) analysis was performed using a panel of intron-based primers designed from the genomic sequences of the RON gene [29] . The amplified DNA fragments were also sequenced as described above.
Establishment of CoTr or MDCK cells expressing RON or variant.
The cDNA encoding human RON or RON⌬160 was subcloned into the mammalian expression vector pDR2 (Clontech). Transfection of CoTr cells or MDCK cells with the vector was performed with transfection reagent DOTAP (Roche) as described [13] . Cells were selected with 200 g/ml of hygromycin B (Gibco). RON-expressing CoTr cells were enriched by mAb ID2-coated Dynal beads (Dynal Inc.) according to the manufacturer's protocol. Expression of the RON protein was determined by Western blotting using rabbit anti-RON IgG.
Immunoprecipitation and Western blotting. Cells (3 ϫ 10 6 cells from each line) were lysed in 200 l lysis buffer (50 mM Tris, pH 7.45, 0.15 mM NaCl, 2 mM EDTA, 0.5% NP-40, 0.5% Triton X-100, 100 M sodium vanadate, 5 g/ml of leupeptin, aprotinin, and soybean trypsin inhibitor). Proteins were mixed with mAb ID2 (1 g) coupled with Protein G-Sepharose beads. Samples were separated in a 8% polyacrylamide gel under reduced conditions and transferred to Immobilon-P membrane (Millipore, Bedford, MA). Western blotting was performed with rabbit IgG to RON peptide or mAb 4G10, followed by goat anti-rabbit or mouse IgG conjugated with HRP. The reaction was developed with ECL reagents and recorded on film.
In vitro kinase assay. The assay was performed as described [28] with slight modifications. Briefly, cells were incubated in serum-free medium overnight and then lysed in lysis buffer. To determine RON kinase activity, RON was immunoprecipitated with mAb ID2 and then mixed for 30 min with 10 Ci [␥-
32 P]ATP in 30 l of kinase buffer (20 mM Hepes, pH 7.50, 20 mM ␤-glycerol phosphate, 10 mM PNPP, 10 mM MgCl 2 , 10 mM DTT, 50 M sodium vanadate, 20 M ATP). In this assay, RON serves as its own substrate (autophosphorylation). For measuring JNK activity, cellular proteins (250 g from each cell line) were mixed with 4 g GST-c-Jun protein (amino acids 1-79) bound to GST-agarose beads. The reaction was carried out with 5 Ci [␥-
32 P]ATP in 30 l kinase buffer at 30°C for 20 min. The beads were washed with kinase buffer once and then with PBS containing 0.05% Triton X-100. The phosphorylated proteins were eluted in sample buffer with 2-ME, resolved by SDS-PAGE, and exposed to film.
Cell migration and invasion assay. These assays were conducted as described [13, 18] . For the migration assay, a multiwell chemotaxis chamber was used. The bottom wells were filled with 30 l DMEM/well containing different amounts of MSP in duplicate and then covered with a collagen IV-coated membrane. Upper wells were filled with 45 l/well of cell suspension (2 ϫ 10 6 cells/ml in DMEM). The chamber was disassembled after a 5-h incubation at 37°C. For Matrigel invasion assay, Trans-well chambers (Costar) were used. The membranes were coated with Matrigel (15 g per membrane, Collaborative Biomedical Products). The chambers were incubated for 36 h. Cells that migrated or invaded the Matrigel were fixed with a Hemo-Staining Kit (Fisher Scientific) and then counted in three randomly selected areas. Results were expressed as the number of migrated or invaded cells per field.
DNA fragmentation assay. Cells (1 ϫ 10 6 per dish) were cultured in DMEM with 1% FBS and pretreated with 5 nM MSP or EGF for 60 min. The IgM antibody to Fas (1 g/ml, clone CH11, Upstate Biotechnology, Inc.) was then added for 24 h. After incubation, genomic DNAs were isolated as described above. DNA fragmentation was determined by running 5 g DNA of each sample per lane in 1% agarose gel. Separated DNAs were stained with ethidium bromide and photographed.
Hoechst dye 33258 fluorochrome staining assay for apoptotic cells.
The assay was done as previously described [30] . Treatment of cells with MSP and mAb CH11 was done as described above. After incubation for different times, cells were fixed with 3% paraformaldehyde for 5 min and washed with PBS. Apoptotic cells were stained with Hoechst dye 33258 (1.5 g/ml) for 10 min followed by a wash with distilled water. Stained nuclei were visualized using a fluorescence microscope (Nikon). A minimum of 200 cells were counted in each sample. Apoptotic cells were expressed as a percentage of the total counted nuclei.
RESULTS

Expression of RON in Human Colon Carcinoma Cell Lines
Eight colon epithelial cell lines were used to determine the levels of RON expression. Cellular proteins were immunoprecipitated and subjected to Western blotting using a pair of antibodies specific to RON. The results are shown in Fig. 1A . RON was barely detectable in normal epithelial FHC and SV-40 transformed CoTr cells. In contrast, all six carcinoma cell lines expressed RON. High levels of RON were found in Colo201, HCT116, HT-29, and SW837. DLD-1 cells expressed relatively low levels of RON. In HT29 cells, a protein with a molecular mass of 135 kDa was detected, which represents a novel RON variant (see details below). SW620 cells also expressed a RON variant with a molecular mass of around 140 kDa, which is smaller than the normal RON ␤ chain (150 kDa). We then studied whether RON is constitutively active in colon carcinoma cells. Tyrosine phosphorylation of RON was determined when cells were stimulated with or without MSP. The results are shown in Fig. 1B . The high levels of spontaneous RON phosphorylation were detected in all three carcinoma cell lines. The addition of MSP further increased tyrosine phosphorylation of RON in colo201 and HCT116 cells, but had no effect on SW837 cells. Similar results were also found in HT-29 cells (data not shown). We further measured the kinase activity of RON. High levels of spontaneous kinase activity were observed in HCT116, SW620, Colo201, DLD-1, and HT-29 cells even without MSP stimulation. These results are shown in Fig. 1C . Interestingly, p135 expressed by HT29 cells also showed spontaneous kinase activity. These results, together with data shown in Figs. 1A and 1B, suggest that RON and its variants are overexpressed and constitutively activated in these colon carcinoma cell lines.
Induction of JNK Kinase Activities in Colorectal Carcinoma Cells
To determine whether activated RON stimulates intracellular signaling pathways, HCT116 and Colo201 cells were incubated with MSP and their JNK kinase activities were determined. The results are shown in Fig. 2A . Spontaneous JNK kinase activities were seen in these two cell lines. MSP stim- 5 cells of each cell line were used for immunoprecipitation with mAb ID2 (1 g) bound to protein G-Sepharose beads. RE-7 cells were used as positive control. Proteins were separated in 8% SDS-PAGE under reduced conditions and transferred to the membrane. Western blotting was performed using rabbit IgG anti-RON peptide. A protein band with a molecular mass of 110 kDa in the RE-7 blot is a trypsin-digested product (occurs only in trypsin-treated RE-7 cells and confirmed by protein microsequencing analysis). (B) Cells were stimulated with or without 5 nM MSP for 10 min at 37°C. RON was immunoprecipitated as described in (A). The mAb 4G10 was used to detect phosphorylated RON in Western blotting. (C) Cells were serum-starved overnight before lysis. Unstimulated RE-7 cells were used as control. The in vitro kinase assay was performed as detailed under Materials and Methods. A low level of spontaneous RON kinase activity was observed in RE-7 cells.
ulation further increased JNK kinase activity in HCT116 cells, but had no effect on Colo201 cells, which displayed extremely high levels of spontaneous JNK activity. The maximal JNK activity in HCT116 cells was seen 15 min after addition of MSP (Fig. 2B) . We also found that MSP increases JNK kinase activities in SW620 cells, but not in HT29 cells, which also expressed high levels of JNK activity spontaneously (date not shown).
Molecular Cloning of a RON Variant in HT-29 Cells
As shown in Figs. 1A and 1C , a protein with a molecular mass of around 135 kDa was detected in HT29 cells. Because the protein reacted with specific antibodies to RON, we reasoned that this protein is a novel RON variant. By using RT-PCR-based cloning techniques as illustrated in Fig. 3, a formation about the genomic structure of the human RON gene [29] , we found that the deletion of 109 amino acids occurs at exons 5 and 6, which resulted in direct connection of the last amino acid of exon 4 with the first amino acid of exon 7. The expected product (designated RON⌬160) is a 160-kDa protein with a regular ␣ chain (40 kDa), and a short form of the ␤ chain (135 kDa). The 135-kDa band shown in HT-29 cells in Fig. 1A is the short form of the RON ␤ chain. Expression of the cDNA encoding RON⌬160 in MDCK cells confirmed that this is the case (Fig. 5) . Biochemical and biological characterization of the RON⌬p165 is currently under way and will be published elsewhere.
Mutational Analysis of the RON Gene in Colon Carcinoma Cell Lines
To determine whether constitutive activation of RON is caused by mutations in the kinase domain of the RON gene, genomic DNAs were isolated from HT29, DLD-1, HCT16, SW620, and SW837 cells. PCR-SSCP was performed using a panel of intron-based primers covering exons 14 to 20 of the RON gene. The amplified DNA fragments were also sequenced. No mutations were found in the kinase domain of the RON gene in these five carcinoma cell lines. However, in HT29 and SW620 cells, a change at position 4031 from A to G (single-nucleotide polymorphism) was identified. This single nucleotide substitution results in the change of Arg 1344 into Gly. These data indicate that the constitutive activation of RON in these colon carcinoma cells is not caused by mutations in the kinase domain of the RON gene. 
Expression of RON in CoTr Cells and Motile-Invasive Phenotypes Induced by MSP
To determine whether activation of RON in colon epithelial cells induces motile-invasive activities, we transfected colon epithelial CoTr cells with the pDR2 expression vector containing the RON cDNA and obtained cells expressing high levels of RON. Using these RON-expressing CoTr cells, we tested RON-mediated cell motility. The results are shown in Fig. 6 . RON expressing CoTr cells migrated in a MSP concentration-dependent manner. Maximal cell migration was observed when 8 nM MSP was added. CoTr cells transfected with pDR2 alone did not migrate toward MSP. We also tested the effect of MSP on the migration of HCT116 cells (Fig. 6) . Although high levels of spontaneous migration were observed, MSP stimulation further increased HCT116 cell migration.
The invasive activities of RON-expressing CoTr cells were also tested in Matrigel invasion assay. The results are shown in Table 1 
Protection by MSP of RON-Expressing CoTr Cells against Apoptosis
To determine whether RON activation transduces survival signals in colon epithelial cells, we stimulated RON-expressing CoTr cells with Fas-activating mAb. The anti-apoptotic effect of MSP was determined by DNA fragmentation assay. The results are shown in Fig. 7A . In control CoTr cells, no DNA fragmentation was observed. Stimulation of cells with Fas-activating mAb resulted in DNA ladder formation. A similar effect was also seen when RON-expressing CoTr cells were used. However, the apoptotic effect was significantly reduced when MSP was added to the culture of RON-expressing CoTr cells. As a control, EGF also reduced the apoptotic effect of mAb CH11 on CoTr cells (Fig. 7A) . To further confirm these results, we per- 
DISCUSSION
The main findings in this report are that RON is overexpressed and constitutively activated in a panel of human colon carcinoma cell lines, but not in normal and SV-40-transformed colon epithelial cells. Moreover, a novel splicing product of RON was identified and cloned from HT-29 cells. This RON variant is also constitutively active. Our results further show that the expression and activation of RON induce migration and matrix invasion of colon epithelial CoTr cells and certain colon carcinoma cells and protect these cells from apoptotic death induced by Fas-activating mAb. These data indicate that RON expression is deregulated in colon carcinoma cell lines. They also suggest that abnormal activation of RON might play an important role in vivo in regulating motile-invasive phenotypes of colorectal carcinomas.
The roles of RON in the progression of epithelial tumors are largely unknown. Previous studies have shown that the forced expression of wild-type RON in rodent fibroblasts does not cause cell transformation, instead, it induces the motile-invasive phenotypes [18] . The data presented in this study show that abnormal expression and activation of RON occur in a panel of colon carcinoma cell lines, but not in normal and SV-40-transformed colon epithelial cells. The high levels of RON accumulation are particularly evident in HT29, Colo201, HCT116, and SW837 carcinoma cells. These results are in line with a previous report using two highly sensitive and specific mAbs in detecting RON expression in different types of human tissue [31] . It was shown that normal human colon epithelial cells express low levels of RON. In contrast, RON is highly expressed in two colon carcinoma cell lines [31] . Interestingly, a similar expression pattern of RON is also observed in human primary breast carcinoma tissues and cell lines [26] . As reported, RON expression is relatively low in normal breast epithelial cells and in benign lesions (adenoma and papillomas), but increases significantly in breast carcinoma cells [26] . These data, together with ours, suggest that cellular mechanisms, which control RON expression, are dysfunctional in colon and breast carcinoma cells. They also indicate that the regulatory systems that govern RON activation and inactivation are deregulated. Since expressing a gene product and controlling its enzymatic activity can occur at different levels, such as gene amplification, protein stability, and phosphorylation status, it will be of interest in the future to find a cellular mechanism(s) that regulates RON expression and activation in these colon cancer cells. Overexpression and constitutive activation of RON in carcinoma cells also provide evidence that RON probably plays little role in initiating epithelial tumors, but is actively transcribed and functional in carcinoma cells [18, 26] . Our present results support this notion. As illustrated in Figs. 6 and 7, we found that the accumulation of RON causes increased colon epithelial cell migration, invasion through the extracellular matrix, and survival against apoptotic signals. These data suggest that after stimulation of RON, the cell motile machinery is activated in colon carcinoma cells and in RONtransfected CoTr epithelial cells, which could facilitate tumor metastasis in vivo. Considering these facts, we believe that the biological significance of RON overexpressed in colon carcinoma cells is to confer the motileinvasive phenotype in the later period of tumor progression, particularly at the metastatic stages.
Identification of a novel RON variant, namely RON⌬160, from HT-29 cells is an interesting finding. To our knowledge, this is the second naturally occurring human RON variant identified in tumor cells derived from the human gastrointestinal tract. Previously, a RON variant, designated ⌬-RON, with a molecular mass of 165 kDa, was found in human stomach cancer cell line KATO III [27] . ⌬-RON has an in-frame deletion of 49 amino acids in the extracellular domain of the RON ␤ chain. The deletion prevents the proteolytic conversion of ⌬-RON into the two-chain form and causes the protein to be retained in the cytoplasm [27] . A recent report using RT-PCR techniques has shown that the deletion of these 49 amino acids also occurs in the RON mRNAs isolated from human primary colon carcinoma tissues [34] , suggesting that ⌬-RON is present in primary colon tumors. In our Western blot analysis using six colon carcinoma cell lines, we did not find ⌬-RON. Instead, we detected RON⌬160. Our cloning and preliminary studies have revealed that RON⌬160 has several unique properties. First, RON⌬160 has an in-frame deletion of 109 amino acids in the extracellular domain of the ␤ chain. These 109 amino acids are encoded by two exons of the RON gene, exons 5 and 6. Second, RON⌬160 is first synthesized as a single-chain precursor (pro-RON⌬160) and then converted into the two-chain form. Unlike ⌬-RON, the deletion of 109 amino acids did not affect the proteolytic processing of RON⌬160. Third, the deletion of 109 amino acids, containing three cysteines, results in unbalanced numbers of cysteine residues in the extracellular domain of the RON ␤ chain. This could result in abnormal dimerization causing the constitutive activation of RON⌬160. As reported previously, the abnormal activation of ⌬-RON is caused mainly by the unbalanced cysteine residues in the extracellular domain of the RON ␤ chain due to the 49-amino-acid deletion [27] . We reason that the same mechanism may also apply to the constitutive activation of RON⌬160. Clearly, the generation of RON⌬160 provides a molecular mechanism for posttranscriptional activation of RON in the HT29 carcinoma cell line. Moreover, because the abnormal activation of RON led to cell migration, dissociation, and invasion [18] , it is reasonable to think that RON⌬160 might play a critical role in regulating the motile-invasive phenotypes of colon carcinoma cells. Biochemical and biological characterizations of RON⌬160 are currently under way.
The findings that RON is constitutively active in these colon cancer cells and that HT29 cells contain the unconventional RON⌬160 prompted us to see whether point mutations occur in the RON gene. As noted in the Introduction, the RON gene belongs to the MET protooncogene family. Germline and somatic mutations of the MET gene, particularly at the kinase domain, were identified in hereditary human papillary renal carcinoma [4, 19] . Moreover, the oncogenic form of RON could be artificially created by point mutations at the kinase domain of the RON gene [33, 34] . These nucleotide substitutions mimic naturally occurring mutations found in the C-Kit and RET oncogenes [35, 36] . We searched for point mutations in the kinase domain of the RON gene using several intron-based primers that cover the kinase domain. PCR-based SSCP and DNA sequencing have been widely used to determine potential mutations in candidate genes [4, 19] . Five human carcinoma cell lines, HT29, DLD-1, HCT116, SW620, and SW837, were screened. However, no mutations were found except for a single-nucleotide polymorphism (A4031G) identified in HT29 and SW620 cells. These results indicate that the constitutive activation of RON is not caused by an abnormality in the kinase domain of RON in these colon cancer cells. Rather, it probably resulted from the overexpression of the receptor protein leading to dimerization and activation [37] . It is also possible that other mechanisms such as posttranslational modifications in the RON kinase domain and deregulated cellular phosphorlyation status contribute to the constitutive activation of RON. One intriguing aspect is that although numerous genomic alterations occur in colon carcinoma cells [38] , the integrity of the kinase domain of the RON gene is still intact. However, since our mutational studies were focused only on the kinase domain of the RON gene, we cannot rule out the possibility that mutations occur in other regions. Also, we do not know whether any posttranslational modifications occur in the kinase domain of RON, which might cause RON activation. Therefore, more studies are needed to determine whether the RON gene has mutations in primary colon carcinoma cells and to study whether any modifications result in increased kinase activity.
The survival of epithelial carcinoma cells in a local environment and their subsequent invasion into surrounding tissues are complicated processes involving many factors [10] . The members of the MET family have the ability to activate different pathways and provide signals for the survival of epithelial tumor cells and facilitate them to metastasize [11, 39, 40] . In this sense, it is not surprising that RON activation not only mediates cell migration and invasion, but also protects cells from apoptosis. Many studies have indicated that among signaling pathways activated by receptor tyrosine kinases, PI-3 kinase and AKT are essential in regulating cell growth, migration, and survival [41] . The requirement for PI-3 kinase and AKT in EGF receptor-mediated protection of epithelial cells against Fas-induced apoptosis has been demonstrated [42] . PI-3 kinase is also required for MET-mediated cell scattering and migration [43] . Our previous data have shown that activated RON increases PI-3 kinase activity and causes its association with RON [25] . Functional studies further demonstrated that PI-3 kinase is required for RON-mediated cell shape change and migration [25, 44] . With these data in mind, we reason that PI-3 kinase might play a critical role in transducing survival signals of RON. A recent study demonstrated that this is the case. The PI-3 kinase-AKT pathway is actively involved in the RON-mediated survival of epithelial cells [45] . Thus, regulation of PI-3 kinase appears to be a key element in RON-mediated cellular activities including cell migration, invasion, and survival.
